US2018207230A1PendingUtilityA1

Autoclavable suspensions of cyclosporin a form 2

Assignee: ALLERGAN INCPriority: Nov 15, 2011Filed: Mar 19, 2018Published: Jul 26, 2018
Est. expiryNov 15, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61P 37/08A61P 37/06A61P 27/04A61P 27/02A61K 9/0048C07K 1/306C07K 7/645A61K 47/32A61K 38/13A61K 47/36A61K 47/38
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of making a formulation of cyclosporin A, the method comprising the steps of
 a) dissolving cyclosporin A form 2 in solution;   b) autoclaving the solution;   c) adding a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127.   
     
     
         2 . A method of making a formulation of cyclosporin A, the method comprising the steps of
 a) dissolving in solution a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127;   b) adding to the solution cyclosporin A Form 2;   c) autoclaving the resulting mixture.

Join the waitlist — get patent alerts

Track US2018207230A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.